BiomX Inc. Reports Better-than-Expected Earnings

May 15, 2025 — BiomX Inc., a microbiome company specializing in phage therapies for chronic diseases, has reported its earnings for the quarter ending March 31, 2025. The company, which is listed on the NYSE American, announced a GAAP earnings per share (EPS) of -$0.33, surpassing analysts’ expectations by $0.03. This performance comes as a positive surprise given the anticipated loss of $0.36 per share, as forecasted by two analysts.

In the previous year’s corresponding quarter, BiomX reported a loss of $2.78 per share, indicating a significant improvement in its financial performance. Despite this positive EPS surprise, the company’s revenue remained flat at $0.0 million, consistent with the previous year’s figures. Analysts had projected a similar revenue outcome for the quarter.

Looking ahead, two analysts have set expectations for the current fiscal year, predicting a loss of $1.53 per share, a slight increase from the $1.47 per share loss reported in the prior year. Revenue forecasts remain unchanged at $0.0 million for the fiscal year.

BiomX Inc., headquartered in Ness Ziona, Israel, focuses on developing customized phage therapies targeting harmful bacteria associated with conditions such as inflammatory bowel disease (IBD), colorectal cancer (CRC), and skin-related bacterial issues. The company went public on the New York Stock Exchange on December 14, 2018.

As of May 4, 2025, BiomX’s stock closed at $0.577, with a 52-week range between $0.477 and $4.90. The company’s market capitalization stands at approximately $14.4 million.

In related news, the chronic pruritus market, which could potentially intersect with BiomX’s therapeutic focus, is anticipated to expand at a compound annual growth rate (CAGR) of 8.6% from 2020 to 2034. This growth is driven by innovative therapies and an increasing prevalence of chronic pruritus due to factors such as an aging population and improved diagnostic awareness among healthcare professionals.

For more information on BiomX Inc. and its initiatives, visit their website at www.biomx.com .